Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cytosorbents Corporation - Common Stock (NQ:CTSO)

0.7066 +0.0844 (+13.56%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytosorbents Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Cytosorbents Corp (NASDAQ:CTSO) Posts Mixed Q3 2025 Results Amidst Stock Volatility ↗
Cytosorbents Q3 2025 earnings show a mixed quarter, beating EPS estimates but missing on revenue. The stock saw volatility despite a strengthened balance sheet. 
Via Chartmill
News headline image
Cytosorbents (CTSO) Q3 2025 Earnings Transcript ↗
Cytosorbents (CTSO) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
News headline image
Deep Dive Into CytoSorbents Stock: Analyst Perspectives (5 Ratings) ↗
 
Via Benzinga
News headline image
Wednesday's pre-market session: top gainers and losers ↗
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
CytoSorbents's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Insights into CytoSorbents's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Expert Outlook: CytoSorbents Through The Eyes Of 7 Analysts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Demystifying CytoSorbents: Insights From 5 Analyst Reviews ↗
 
Via Benzinga
News headline image
CytoSorbents Corp (NASDAQ:CTSO) Reports Mixed Q2 2025 Earnings with Revenue Beat and Narrower Loss ↗
CytoSorbents (CTSO) reported Q2 2025 results with revenue of $9.62M, beating estimates, and a narrower EPS loss of -$0.05. Shares rose 4.32% post-earnings amid steady demand for CytoSorb. 
Via Chartmill
News headline image
A Glimpse Into The Expert Outlook On CytoSorbents Through 5 Analysts ↗
 
Via Benzinga
News headline image
Top movers in Wednesday's session ↗
Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
These stocks are moving in today's session ↗
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Gapping stocks in Wednesday's session ↗
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
Deep Dive Into CytoSorbents Stock: Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
Demystifying CytoSorbents: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 14, 2025 ↗
 
Via Benzinga
News headline image
The Analyst Verdict: CytoSorbents In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 31, 2025 ↗
 
Via Benzinga
News headline image
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller
The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing... 
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants
1,417,208 Series A Right Warrants Exercised at $1.13 Per Share, Providing $1.6 Million in Aggregate Gross Proceeds 
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai
From CytoSorbents
Via GlobeNewswire
News headline image
Health Care Equipment Supplier CytoSorbents Shares Dip Despite Projected Revenue Growth ↗
CytoSorbents is progressing with U.S. FDA and Health Canada reviews for its DrugSorb-ATR device. 
Via Benzinga
Topics Supply Chain
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.